Modular Medical Inc

Modular Medical Inc(MODD)の株式分析

$1.330

+0.052 (+3.91%)終値時点

Loading chart…
高値
1.455
始値
1.360
出来高加重平均価格
1.35
出来高
54.69K
時価総額
50.76M
安値
1.255
売買代金
73.65K
EV/EBITDA(TTM)
0.00

Modular Medical, Inc. is a medical device company. The Company is focused on the design, development, and commercialization of insulin pumps using technology to increase pump adoption in the diabetes marketplace. The Company's product seeks to serve both the type 1 and type 2 diabetes markets for those individuals requiring insulin. MODD1, its product, is a high-precision pump. MODD1's features include three parts - one reusable, two disposable - snap together to form the working system; one button interface; 90-day reusable, three-day disposable; removable system, slim profile, lighter weight, and no external controller required, no charging and no battery replacement. Its pump product comprises the pump, a disposable cartridge that holds the insulin reservoir, a baseplate that affixes the pump product to the user's body and the infusion set, which includes a cannula to infuse the insulin into the body.

www.modularmedical.com

AI分析 of Modular Medical Inc (MODD)

売り

Modular Medical Inc (MODD) is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $1.33, with an RSI of 24.997 indicating it is oversold. The company has reported a staggering year-to-date change of -88.48% and a 1-year change of -91.30%, reflecting severe declines in stock value. Furthermore, the forward P/E ratio is 0, suggesting no earnings growth is expected in the near future. The main risk is the continued negative net income, which reached -7,790,000 USD in Q2 2026. Given these factors, it is advisable to sell rather than buy at this time.

バリュエーション指標

Modular Medical Inc(MODD)の現在の予想PERは0.00で、5年平均は-2.57です。

予想PER

大幅な割高
5年平均 P/E
-2.57
現在のP/E
0.00
割高
-1.37
割安
-3.77

予想EV/EBITDA

大幅な割安
5年平均 EV/EBITDA
0.00
現在のEV/EBITDA
0.00
割高
0.00
割安
0.00

予想PSR

適正
5年平均 P/S
136.48
現在のP/S
3.80
割高
395.58
割安
-122.61

イベントタイムライン

2026-10-15 (ET)

09:30:00

Modular Medical Launches Digital Education Resources for Diabetes Patients

2026-09-04 (ET)

08:30:00

Modular Medical Secures Contract with U.S. National Pharmacy Benefit Manager

2026-09-03 (ET)

08:30:00

Modular Medical Receives FDA Approval for Software Enhancements

2026-08-03 (ET)

08:30:00

Modular Medical Plans to Launch Tubeless Patch Pump in Five U.S. Markets in October 2026

2026-07-23 (ET)

08:30:00

Modular Medical Forms Pivot Innovation Council

ニュース

MODD のよくある質問 — Alphio AI が回答

Modular Medical, Inc. is a medical device company. The Company is focused on the design, development, and commercialization of insulin pumps using technology to increase pump adoption in the diabetes marketplace. The Company's product seeks to serve both the type 1 and type 2 diabetes markets for those individuals requiring insulin. MODD1, its product, is a high-precision pump. MODD1's features include three parts - one reusable, two disposable - snap together to form the working system; one button interface; 90-day reusable, three-day disposable; removable system, slim profile, lighter weight, and no external controller required, no charging and no battery replacement. Its pump product comprises the pump, a disposable cartridge that holds the insulin reservoir, a baseplate that affixes the pump product to the user's body and the infusion set, which includes a cannula to infuse the insulin into the body. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Modular Medical Inc (MODD) is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $1.33, with an RSI of 24.997 indicating it is oversold. The company has reported a staggering year-to-date change of -88.48% and a 1-year change of -91.30%, reflecting severe declines in stock value. Furthermore, the forward P/E ratio is 0, suggesting no earnings growth is expected in the near future. The main risk is the continued negative net income, which reached -7,790,000 USD in Q2 2026. Given these factors, it is advisable to sell rather than buy at this time.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める